European approval for Revestive(Takeda) for Short Bowel Syndrome

Takeda Pharmaceutical Company Limited and NPS Pharmaceuticals, Inc. jointly announced that the European Commission (EC) has granted European market authorization for the medicinal product Revestive (teduglutide), known as Gattex in the US, as a once-daily treatment for adult patients with Short Bowel Syndrome. The marketing authorization follows a positive opinion issued on June 21, 2012, by the Committee for Medicinal Products for Human Use of the European Medicines Agency.Following the authorization, Takeda intends to provide patient access to Revestive within Europe initially through a Named Patient Program.